Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Gepirone

Plain-language summaryIntrigue 64 / 100

Gepirone (Exxua) finally reached FDA approval in 2023, more than thirty years after its initial development at Bristol-Myers Squibb began in the 1980s. The 5-HT1A partial agonist had been rejected by the FDA multiple times before Fabre-Kramer eventually pushed an extended-release formulation across the finish line for major depressive disorder. The selling point versus standard SSRIs is essentially zero sexual dysfunction, which is the side effect that drives many patients off serotonergic antidepressants. Mechanistically it is in the same azapirone family as buspirone but with substantially more 5-HT1A intrinsic activity, which appears to translate into antidepressant rather than just anxiolytic effects. Real-world prescribing data are still accumulating. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

FDA-approved azapirone that took 30 years to clear; limited novelty for bench researchers in 2026

Look, gepirone is a compound with an unusual story: 30-plus years in development, multiple FDA rejections, and a 2023 approval under Exxua that felt more like the FDA eventually relenting than a decisive efficacy win. That history matters when you’re trying to figure out what this compound actually tells you.

The mechanism is 5-HT1A partial agonism, and if that sounds familiar, it should. Buspirone has been doing the same thing since 1986. Gepirone’s affinity sits around 19 nM with roughly 60 percent intrinsic activity and minimal D2 involvement, which is a slightly cleaner pharmacological profile than buspirone in some respects. The active metabolite 1-PP shares some alpha-2 receptor activity with buspirone’s 1-PP as well. The ER formulation is the real packaging innovation here, turning a three-times-daily regimen into once-daily dosing. But none of that adds up to a novel mechanism or a new research angle.

What gepirone has going for it clinically is the absence of sexual dysfunction. SSRIs are notorious for it, and a serotonergic antidepressant that sidesteps that tolerability liability is genuinely valuable in the clinic. Multiple phase 3 trials eventually demonstrated sufficient efficacy for MDD to clear the regulatory bar. That earns real evidence quality and translational signal scores, and those pull the overall number up from where novelty and mechanism alone would leave it.

Heres the thing for bench researchers, though: buspirone already exists as your 5-HT1A partial agonist reference compound. If you’re running a rodent depression or anxiety model and need a selective 5-HT1A partial agonist, gepirone offers marginal incremental probe value over buspirone, which is cheaper, better-characterized in animal models, and has four decades of comparative literature behind it. The gepirone advantage is the ER formulation and the cleaner D2 profile in humans; neither of those translates to bench utility in any meaningful way.

We dont think gepirone is a bad compound. The 2023 approval is real, the tolerability profile is a genuine clinical advance, and theres some value in a 5-HT1A partial agonist with a depression-focused regulatory history. But the mechanism is mature, the novelty is low, and the primary differentiation is a clinical tolerability story rather than a mechanistic one. A serious investigator running a 5-HT1A research program already has buspirone. Adding gepirone to that bench doesn’t open new questions. It confirms old answers in a slightly better-tolerated package.

Novelty

22

Mechanism promise

28

In-category differentiation

30

Evidence quality

58

Translational signal

62

Research bench value

35

Rationale Gepirone earns real points on evidence quality and translational signal from its 2023 FDA approval for MDD, but its mechanism is decades-old single-receptor 5-HT1A partial agonism with buspirone already serving as the reference probe; the 30-year regulatory slog reflects modest differentiation in a crowded space, leaving it a low-priority bench target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist

An azapirone 5-HT1A partial agonist developed for major depressive disorder; FDA-approved in 2023 after a 30-year development cycle.

Abstract

Gepirone (4,4-dimethyl-1-{4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}-2,6-piperidinedione; CAS 83928-76-1; molecular formula C19H29N5O2; molecular weight 359.47) is an azapirone 5-HT1A partial agonist developed by Bristol-Myers Squibb and Fabre-Kramer over a 30-plus-year development cycle, ultimately approved by the FDA in 2023 under the trade name Exxua for major depressive disorder. The compound is structurally and mechanistically similar to buspirone: 5-HT1A affinity approximately 19 nM with intrinsic activity approximately 60 percent; minimal D2 affinity; active metabolite 1-PP. Distinct from buspirone in development trajectory (positioned for depression rather than anxiety) and in being formulated as extended-release for once-daily dosing. The approved indication is MDD; the principal selling point versus SSRIs is absence of sexual dysfunction (a major SSRI tolerability complaint). Plasma half-life is 18 hours (ER formulation); metabolism is via CYP3A4. Used as a reference 5-HT1A partial agonist with depression-focused clinical development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-250Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pregabalin

Plain-language summaryIntrigue 67 / 100

Pregabalin (Lyrica) is a GABA look-alike that does not actually bind any GABA receptor or GABA transporter. Instead it binds the alpha-2-delta subunit of voltage-gated calcium channels, which reduces the release of glutamate and several other neurotransmitters at synapses. The compound came out of Northwestern University and was developed by Pfizer; the FDA approved it in 2004. It is widely used for neuropathic pain (diabetic neuropathy, postherpetic neuralgia), fibromyalgia, partial seizures, and generalized anxiety. Onset is rapid by anxiolytic standards (within hours to a few days). It produces euphoria in some patients and is a Schedule V controlled substance in the US owing to abuse potential, particularly in people with prior opioid or sedative use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

55/100

Canonical alpha-2-delta reference probe; mature approved drug with excellent evidence but low frontier research value

Look, pregabalin is a real drug. FDA-approved 2004, multiple confirmed indications, linear PK, Ki of roughly 22 nM at alpha-2-delta-1. The Silverman lab at Northwestern built something that actually works, and the clinical literature is not ambiguous. If you need a compound to establish alpha-2-delta subunit contribution in a pain or seizure model, pregabalin is what you reach for. That’s the honest case for having it in the library.

Here’s the thing though: when a compound has been FDA-approved for over two decades, that’s not a research signal, thats a research endpoint. The mechanism is thoroughly mapped. Presynaptic alpha-2-delta-1 binding reduces calcium influx, and downstream transmitter release (glutamate, norepinephrine, substance P, CGRP) drops accordingly. Elegant when it was first described. Now it’s a textbook entry. There’s no serious literature debate about what pregabalin does; the conversation moved on.

Differentiation within its class is real. Pregabalin has linear pharmacokinetics versus gabapentins notorious saturable absorption, and the potency advantage is meaningful (roughly three to four times more potent by binding affinity). So within the alpha-2-delta ligand family, it’s clearly the reference standard. But the alpha-2-delta class itself isn’t a frontier anymore. The interesting open questions in neuropathic pain and neuromodulation have migrated toward sodium channel isoform selectivity, glial targets, and dorsal horn circuit biology. Pregabalin doesn’t illuminate any of those questions.

The Schedule V status in the US reflects real, if modest, abuse liability. At supratherapeutic doses users describe benzodiazepine-like euphoria, which is mechanistically interesting but not research-interesting in the Kodiac sense. What we dont love is the positioning risk: this compound is well-known enough that investigators sometimes treat it as background infrastructure rather than an experimental variable, which tends to produce lazy study designs.

Where we think pregabalin earns its place is narrow and specific. If your research program needs to pharmacologically isolate alpha-2-delta subunit contributions from other calcium channel biology, pregabalin is the tool. Its bioavailability, linear kinetics, and established selectivity profile make it substantially cleaner than alternatives. That’s a real but circumscribed bench value. The evidence quality is outstanding because it’s an approved drug; the translational signal is excellent for the same reason. But those scores reflect a compound thats been characterized, not a compound worth characterizing. Score it accordingly.

Novelty

20

Mechanism promise

40

In-category differentiation

60

Evidence quality

82

Translational signal

80

Research bench value

70

Rationale Pregabalin scores well on evidence and translational signal because it is an approved drug with robust phase 3 data, but those same facts drag novelty and mechanism-promise to the floor. Its library value is almost entirely probe-based: if you are doing alpha-2-delta subunit biology, this is your reference ligand, and that earns it a real but modest score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Alpha-2-delta calcium channel ligand (GABA analog)

A GABA structural analog binding the alpha-2-delta subunit of voltage-gated calcium channels; approved for neuropathic pain, fibromyalgia, and partial seizures.

Abstract

Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid; CAS 148553-50-8; molecular formula C8H17NO2; molecular weight 159.23) is a GABA structural analog developed at Pfizer (Northwestern University origin, Lipton/Silverman) and approved by the FDA in 2004 under the trade name Lyrica. Despite the structural resemblance to GABA, the compound does not act on GABA-A, GABA-B, or GABA reuptake mechanisms; the molecular target is the alpha-2-delta-1 subunit of voltage-gated calcium channels, where high-affinity binding (Ki approximately 22 nM) reduces presynaptic calcium influx and consequent release of glutamate, norepinephrine, substance P, and CGRP. Plasma half-life is 6.3 hours; renal excretion is the principal clearance pathway with linear pharmacokinetics. Approved indications include neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, partial-onset seizures (adjunctive), and generalized anxiety disorder (in EU). The compound has scheduled status (Schedule V in the US) reflecting modest abuse potential at supratherapeutic doses, where users report euphoria and benzodiazepine-like effects. Used as the canonical alpha-2-delta calcium channel ligand reference.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-251Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gabapentin

Plain-language summaryIntrigue 65 / 100

Gabapentin (Neurontin) is the older sibling of pregabalin from Parke-Davis, FDA-approved in 1993, and it works by the same mechanism: binding the alpha-2-delta subunit of voltage-gated calcium channels, with no actual effect on GABA receptors despite the misleading name. The big practical difference from pregabalin is dose-response: gabapentin’s intestinal absorption saturates, so doubling the dose does not double the blood level, which makes high doses inefficient. Approved for postherpetic neuralgia and partial seizures, with massive off-label use for anxiety, sleep, alcohol withdrawal, restless legs, and chronic pain. The Pfizer off-label marketing campaign that drove its sales in the 1990s was the subject of a landmark fraud settlement. Abuse potential is real but lower than pregabalin’s. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Mature alpha-2-delta ligand superseded by pregabalin clinically; still a clean reference probe for VGCC subunit biology

Look, gabapentin has been in the literature since 1993 and the research community has had more than three decades to extract novelty from it. For a bench scientist asking what deserves time right now, this isn’t the answer. But thats not the same as saying it has no place in the library.

The mechanism is genuinely specific: gabapentin binds the alpha-2-delta-1 subunit of voltage-gated calcium channels with a Ki of roughly 80 nM. Despite the name, it has no meaningful activity at GABA-A or GABA-B receptors. What it does is reduce presynaptic calcium influx and downstream neurotransmitter release at sensitized synapses. That mechanism is clean and validated across hundreds of independent studies. The problem is that everyone already knows this. The pharmacology has been squeezed for novelty and the returns have diminished sharply.

What really sinks it as a frontier research target is the pharmacokinetics combined with the availability of better tools. Gabapentin relies on a saturable intestinal transporter for absorption. Bioavailability can hit 80 percent at low doses and collapse to around 27 percent at 1600 mg, producing nonlinear dose-response and frustrating individual variability in clinical work. Pregabalin solved that transporter saturation problem and achieved linear absorption, which is a large part of why it has displaced gabapentin in most new pharmacological programs. If you need a selective alpha-2-delta-1 ligand for a clean assay, you have options and some are meaningfully better.

The clinical evidence base is real and substantial. Multiple large phase 3 trials, FDA approval for postherpetic neuralgia and partial-onset seizures, and an extensive off-label literature covering neuropathic pain broadly, anxiety, alcohol withdrawal, and restless legs syndrome. We don’t find the off-label literature particularly compelling as a research signal. Much of it is small-N, inconsistent in methodology, and complicated by the well-documented history of off-label promotion litigation against Pfizer. The clean translational signal sits in the original approved indications.

As a probe, gabapentin still earns its keep in a narrow context. If you’re studying alpha-2-delta-1 subunit trafficking, presynaptic calcium dynamics in dorsal root ganglia, or the molecular basis of central sensitization, gabapentin is the reference ligand. The literature density means any result you generate is immediately contextualizable. For that specific utility, we actually think it belongs in the library.

What we don’t think is that it qualifies as interesting research territory. The real mechanistic questions in this space are being asked with more selective or structurally novel tools. Gabapentin functions like a positive control: necessary to have, not exciting to use. A score of 41 reflects exactly that balance, strong evidence and clinical history dragging up a compound with very little research novelty left in the tank.

Novelty

20

Mechanism promise

28

In-category differentiation

22

Evidence quality

72

Translational signal

68

Research bench value

55

Rationale Gabapentin scores low on novelty and differentiation because it is a 1993 approval with a well-understood mechanism and a clearly superior successor in most contexts; evidence and translational scores are pulled up by its approved-drug pedigree and large clinical dataset, while bench value is rescued by its canonical role as the alpha-2-delta-1 probe in seizure and pain pharmacology programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA analog calcium channel ligand

A GABA analog binding the alpha-2-delta subunit of voltage-gated calcium channels; the structural and clinical predecessor to pregabalin.

Abstract

Gabapentin (1-(aminomethyl)cyclohexaneacetic acid; CAS 60142-96-3; molecular formula C9H17NO2; molecular weight 171.24) is a GABA analog developed at Parke-Davis (Pfizer) in the 1980s and approved by the FDA in 1993 under the trade name Neurontin. Mechanism mirrors pregabalin: binding to the alpha-2-delta-1 subunit of voltage-gated calcium channels (Ki approximately 80 nM, weaker than pregabalin), reducing presynaptic neurotransmitter release. No direct GABA receptor activity. Plasma half-life is 5 to 7 hours. Distinguished from pregabalin by saturable absorption: oral bioavailability ranges from 80 percent at 100 mg to 27 percent at 1600 mg, producing nonlinear dose-response and unpredictable individual responses at higher doses. Approved for postherpetic neuralgia and partial-onset seizures (adjunctive); off-label use is extensive (anxiety, alcohol withdrawal, restless legs syndrome, hot flashes, hiccups, neuropathic pain of all causes, migraine prophylaxis). The compound has been the subject of extensive off-label promotion litigation and is now scheduled in some US states reflecting abuse potential. Used as the canonical alpha-2-delta-1 calcium channel ligand and a reference compound in seizure pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-252Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hydroxyzine

Plain-language summaryIntrigue 56 / 100

Hydroxyzine (Atarax, Vistaril) is a first-generation antihistamine from UCB, approved in 1956, that crosses the blood-brain barrier readily and produces sedation and anxiolysis as a result. It is FDA-approved for anxiety and pruritus (itching), and unlike benzodiazepines it has no dependence or withdrawal potential, which makes it a useful first-line option for situational anxiety in patients with substance use histories. The trade-off is that the same antihistamine and anticholinergic effects produce dry mouth, constipation, urinary retention, and next-day grogginess. The active leftover after liver metabolism is cetirizine (Zyrtec), the over-the-counter allergy drug, which does not cross into the brain at clinical doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A 1956-approved FDA drug with solid clinical evidence and essentially no research frontier left to explore

Look, hydroxyzine is a real drug. FDA approved in 1956, over a billion patient-exposures, solid randomized data for generalized anxiety and pruritus, a clean non-scheduled status that made it clinically useful before buspirone or the SSRIs arrived. We’re not dismissing it clinically. We’re saying there’s almost nothing here for a bench investigator in 2026 that hasn’t been settled for decades.

The mechanism is H1 antagonism at roughly 2 nM affinity, secondary 5-HT2A blockade around 10 nM, and a weak D2 component. That multi-receptor fingerprint is interesting in the abstract, but it’s fully mapped, well-understood, and not pointing at anything new. The 5-HT2A angle doesn’t give you psychoplastogen biology; the D2 component isn’t the basis for a new antipsychotic story. You’re reading 1980s receptor binding papers when you go looking for mechanism literature here.

What’s genuinely useful about hydroxyzine as a research tool is the metabolite relationship. Hydroxyzine produces cetirizine in vivo, and cetirizine loses CNS penetration because of the carboxylic acid group. That pairing has been used as a probe model to interrogate what H1-mediated CNS penetration actually contributes versus peripheral H1 blockade. Thats a narrow but real utility. If you’re building a pharmacokinetic or CNS-penetration model around first-generation antihistamines, hydroxyzine earns a seat at the table. For anything else, it doesn’t.

The evidence base is strong by the standards of research compounds. Multiple replicated RCTs across anxiety and pruritus indications, decent Hamilton Anxiety Rating Scale data, perioperative sedation trials. The HAMA studies from the 1970s through the 1990s were reasonably well-designed for their era. You’re not dealing with single-lab preclinical data and Croatian rodent models here. But strong evidence for a fully-characterized approved drug is actually the least interesting kind of strong evidence when you’re trying to identify what to study next.

We don’t see a compelling frontier angle. The anxiolysis mechanism isn’t being revisited in a new light. The H1 space isn’t generating exciting new biology. The drug’s non-controlled status is a clinical feature, not a research opportunity. If your program touches first-gen antihistamines as comparators or pharmacokinetic probes, hydroxyzine is a reasonable tool to have documented. As a primary research target in its own right, honestly, you’re working from a 1956 foundation with nowhere obvious to go.

Novelty

12

Mechanism promise

22

In-category differentiation

32

Evidence quality

68

Translational signal

65

Research bench value

45

Rationale Hydroxyzine scores low on novelty and mechanism because it’s a 70-year-old approved drug with a fully characterized H1/5-HT2A/D2 profile; the high evidence and translational scores reflect its genuine approved-drug trial base, but those can’t rescue the overall when the compound offers nothing a serious investigator hasn’t seen. Bench value gets a modest credit for its canonical probe role comparing CNS-penetrant vs. non-penetrant antihistamine effects via its cetirizine metabolite relationship.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation H1 antihistamine anxiolytic

A first-generation piperazine H1 antihistamine with anxiolytic activity; the first non-controlled anxiolytic widely used in psychiatry.

Abstract

Hydroxyzine (2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; CAS 68-88-2; molecular formula C21H27ClN2O2; molecular weight 374.91) is a first-generation piperazine H1 antihistamine developed at UCB and approved by the FDA in 1956 under the trade names Atarax and Vistaril. Distinct from later antihistamines by clinically significant CNS penetration, producing the sedation and anxiolytic effects characteristic of first-generation H1 blockers. H1 affinity approximately 2 nM; secondary 5-HT2A antagonism (Ki approximately 10 nM) and weak D2 antagonism contribute to the anxiolytic profile. The principal active metabolite cetirizine retains H1 antagonism but loses CNS penetration owing to addition of a carboxylic acid group, and is marketed separately as a non-sedating antihistamine (Zyrtec). Plasma half-life is 14 to 25 hours; metabolism is hepatic. Approved for anxiety, pruritus, and as a preoperative sedative; off-label use in insomnia and as a benzodiazepine-sparing anxiolytic. Used as the canonical first-generation H1 antihistamine in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-253Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gaboxadol (THIP)

Our opinion on this compoundNiche research probe

61/100

The canonical extrasynaptic delta-GABA-A probe; therapeutically abandoned but mechanistically irreplaceable for tonic inhibition research

Look, gaboxadol is a weird one to rate because it exists in two completely separate stories simultaneously. The first story is a clinical failure: Lundbeck and Merck took it through Phase 3 in primary insomnia, watched patients experience disorientation and hallucinations, and pulled the plug in 2007. That story is over. The second story is the interesting one, and its the reason gaboxadol belongs in this library at all.

Here’s the thing about the mechanism. Most GABA pharmacology targets synaptic receptors, the alpha1/2/3-beta-gamma2 isoforms that benzodiazepines and z-drugs hit. Those receptors mediate phasic inhibition, fast transient signals. Gaboxadol does something different: it’s a superagonist at extrasynaptic GABA-A receptors bearing the delta subunit, primarily alpha4-beta3-delta and alpha6-beta3-delta, and those receptors mediate tonic inhibition, the continuous low-amplitude background current that sets the excitability baseline of a neuron. Thats a genuinely different biological variable, and most of the GABA pharmacology toolkit doesn’t let you isolate it cleanly.

We think the differentiation here is underappreciated. Muscimol hits both synaptic and extrasynaptic receptors indiscriminately. DS2, a delta-selective PAM, modulates the receptor but doesn’t agonize it directly. If you want to study what delta-subunit tonic GABA-A current actually does in a circuit, gaboxadol is effectively the only clean pharmacological lever. That’s a real niche, and it’s gotten more interesting since the brexanolone and zuranolone data validated the delta-subunit angle for neurosteroid-sensitive states. Labs working on PMDD biology, alcohol use disorder, stress-related changes in inhibitory tone, or sleep architecture at the subunit level are going to want this compound on the shelf.

The evidence picture is decent for a failed drug. Multiple Phase 3 trials ran to completion before the adverse event signal emerged. That means there’s actual human pharmacology data: real EEG effects, real sleep architecture changes, real CNS penetration confirmed by the adverse events themselves. Preclinical literature is solid and multi-lab. The translational signal is real but it points toward a wall therapeutically, which is why the score here isn’t higher overall.

Honestly, if you’re not working on GABA-A subunit biology specifically, this compound probably isn’t your priority. The clinical failure isn’t a reason to ignore it, but it does mean the research community actively using it is a specialist one. For those investigators, it’s close to indispensable. For everyone else, it’s a footnote in GABA pharmacology history with a genuinely interesting mechanism they probably won’t have occasion to use.

Novelty

48

Mechanism promise

68

In-category differentiation

72

Evidence quality

60

Translational signal

45

Research bench value

75

Rationale Gaboxadol failed Phase 3 as a hypnotic due to adverse psychiatric events, but the mechanism is intact and validated; it scores high on differentiation and bench value because no other compound selectively probes extrasynaptic delta-containing GABA-A receptors with the same precision, making it indispensable for labs working on tonic inhibition, neurosteroid sensitivity, or delta-subunit biology specifically.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective extrasynaptic GABA-A delta-subunit agonist

A 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol agonist selective for extrasynaptic GABA-A receptors containing the delta subunit; investigated as a hypnotic.

Abstract

Gaboxadol (THIP; 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; CAS 64603-91-4; molecular formula C6H8N2O2; molecular weight 140.14) is a selective extrasynaptic GABA-A receptor agonist developed at Lundbeck and Merck through the 1990s and 2000s. Distinct from benzodiazepines and barbiturates by selective binding to GABA-A receptor isoforms containing the delta subunit (alpha4-beta3-delta and alpha6-beta3-delta), which are predominantly extrasynaptic and mediate tonic (continuous, low-amplitude) inhibition rather than the phasic (high-amplitude, transient) inhibition mediated by synaptic alpha1/2/3-beta-gamma2 receptors. The compound is a superagonist at delta-containing receptors (efficacy greater than that of GABA itself). Phase 3 trials in primary insomnia (2007) were halted following adverse psychiatric events including disorientation and hallucinations; development was abandoned. The compound retains research utility as the canonical extrasynaptic delta-GABA-A agonist for academic GABA pharmacology and sleep architecture studies. Plasma half-life is approximately 1.5 to 2 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-255Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tofisopam

Plain-language summaryIntrigue 56 / 100

Tofisopam (Grandaxin) is an unusual benzodiazepine from EGIS in Hungary, registered in the 1960s. The chemistry is technically a benzodiazepine, but the substitution pattern (a 2,3-fused ring rather than the standard 1,4-fused ring of diazepam and lorazepam) means it does not bind the classic GABA-A benzodiazepine site at all. As a result it produces anxiolysis without sedation, muscle relaxation, cognitive impairment, or dependence. The actual mechanism is not fully worked out, with proposals including phosphodiesterase inhibition and dopaminergic modulation. Approved across Europe and parts of Asia for anxiety and autonomic dysfunction; never approved in the US. Genuinely interesting pharmacologically because it shows that the benzodiazepine scaffold can do more than activate GABA-A. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

51/100

A structurally distinct non-GABA-A anxiolytic with real probe value and an incompletely mapped mechanism worth investigating

Here’s the thing about tofisopam: it’s not a benzodiazepine in the way that word usually lands. Yes, the diazepine ring is there, but the nitrogen positions are at the 2,3 carbons rather than the 1,4 positions of diazepam or lorazepam, and that single structural difference eliminates binding at the classical benzodiazepine allosteric site on GABA-A receptors entirely. That means no sedation from GABA current potentiation, no muscle relaxation from that pathway, and by most accounts no physical dependence profile that mirrors classical benzos. EGIS Pharmaceuticals in Hungary developed it in the 1960s, and it’s been marketed as Grandaxin in Hungary, France, and several Asian markets for decades under indications that include anxiety, autonomic instability, and post-stress recovery. For a compound this old to still have an incompletely characterized mechanism is either a red flag or a research opportunity depending on how you look at it.

We lean toward opportunity, cautiously. The leading hypotheses for tofisopam’s activity include phosphodiesterase IV (PDE4) inhibition and some form of dopaminergic modulation, possibly both operating in parallel. PDE4 inhibition is not a trivial mechanism: roflumilast got approved for COPD on that axis, and the neuroimmune and cognitive implications of PDE4 in the CNS have attracted serious attention over the last decade. If tofisopam genuinely hits PDE4 with relevant potency in neural tissue, thats a more interesting story than it usually gets credit for. The dopaminergic angle is less characterized but could explain the reported antifatigue and mood-brightening effects that dont fit a pure anxiolytic profile. What we dont have is a clean pharmacological dissection confirming which target drives which effect at clinically relevant concentrations.

The evidence base is the main drag on the score. Tofisopam has human approval, which is real, but the supporting literature is heavily weighted toward Eastern European clinical work from the 1970s through the 1990s, published in journals that dont make modern replication standards easy to verify. There isnt a modern phase 2 or phase 3 RCT benchmarking it against placebo or active comparators with current methodology. The preclinical literature is sparse compared to what you’d want before building a research program around it.

Where tofisopam earns its keep is as a reference tool. If your lab is trying to understand what non-GABAergic, non-serotonergic anxiolysis looks like pharmacologically, it’s essentially the only 2,3-benzodiazepine with a usable human history and commercial availability. That niche is real but narrow. Honestly, it scores where it scores because it’s genuinely interesting as a probe without being important enough in any active research conversation to rank higher. Investigators in autonomic pharmacology or PDE4 neuroimmunology should know it exists.

Novelty

42

Mechanism promise

55

In-category differentiation

60

Evidence quality

40

Translational signal

48

Research bench value

60

Rationale Tofisopam’s 2,3-benzodiazepine scaffold genuinely sidesteps classical GABA-A activity, making it the reference probe for non-sedating, non-dependence-forming anxiolysis via a mechanism that still isn’t fully nailed down; the European approval provides a real human signal, but the evidence base is dominated by older Eastern European literature with limited modern replication, keeping differentiation and bench value from pulling the score higher.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

2,3-benzodiazepine atypical anxiolytic

A 2,3-benzodiazepine without classical GABA-A activity; a non-sedating anxiolytic marketed in Europe.

Abstract

Tofisopam (1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; CAS 22345-47-7; molecular formula C22H26N2O4; molecular weight 382.46) is a 2,3-benzodiazepine developed at EGIS (Hungary) in the 1960s and approved in Hungary, France, and other European and Asian markets under the trade name Grandaxin. Distinct from the 1,4-benzodiazepine class (diazepam, lorazepam, etc.) by the position of the nitrogens in the diazepine ring: the 2,3 isomer does not bind the classical benzodiazepine site on GABA-A receptors and lacks the GABA-A-mediated sedation, anxiolysis, and dependence of conventional benzodiazepines. The mechanism is incompletely characterized; possibilities include phosphodiesterase IV inhibition and modulation of dopaminergic signaling. Plasma half-life is approximately 6 to 8 hours; metabolism is hepatic. Approved indications in markets where registered include anxiety disorders, autonomic instability, and post-stress recovery; off-label use in fatigue and reactive depression. Not approved in the US. Used as a reference 2,3-benzodiazepine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-254Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Propranolol

Plain-language summaryIntrigue 73 / 100

Propranolol (Inderal) is the first commercially successful beta-blocker, developed by James Black at ICI and approved by the FDA in 1967. Black’s work on it earned him the Nobel Prize and reshaped cardiovascular medicine. It blocks both subtypes of beta-adrenergic receptor, dampening the heart’s response to adrenaline as well as the bronchial and metabolic effects. Beyond its many cardiovascular uses, it has a substantial second life in psychiatry and neurology: it is the standard prescription for performance anxiety (one or two tablets before public speaking blunts the heart-pounding and tremor without affecting cognition), is first-line for migraine prevention, and has been studied for trauma memory reconsolidation in PTSD. Lipophilic enough to cross into the brain, which contributes to both its therapeutic and side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Historical cornerstone with almost no remaining research novelty; valuable as a canonical non-selective beta-blocker probe

Look, propranolol is one of the most consequential drugs in the history of pharmacology. James Black’s Nobel Prize was built partly on it. And yet, as a research target in 2026, it’s almost entirely spent. That’s the tension the score reflects, and it’s not a close call.

The cardiovascular evidence base is airtight. Hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor — six approved indications and decades of replicated RCTs sitting behind each of them. The pharmacokinetics have been characterized exhaustively: non-selective beta-1 and beta-2 blockade, 3-to-6 hour half-life, high lipophilicity giving CNS penetration that hydrophilic competitors like atenolol and nadolol simply lack. Those properties earned it permanent status as the reference non-selective beta-blocker. That reference-compound identity is essentially its only remaining research value — real, but narrow.

The most interesting live research angle is the PTSD memory reconsolidation work, and we want to be honest about what that actually is. The mechanistic logic is genuinely clever: noradrenergic signaling in the basolateral amygdala is required for fear memory reconsolidation, so blocking beta-adrenergic receptors during a deliberate recall event should attenuate reconsolidation and weaken the traumatic memory. Pitman’s Harvard MGH group published the original proof-of-concept in 2002. Alain Brunet’s Montreal lab has been the most persistent investigator, including a 2018 randomized trial in PTSD patients showing meaningful symptom reduction. The signal is real. But the 2019 Cochrane review found the evidence base insufficient, effect sizes across studies are modest, and its been 24 years since the founding paper. Calling this novel would be a stretch.

The novelty problem is fundamental. Beta-adrenergic blockade has been understood mechanistically since the 1960s. No new chemistry, no new mechanisms, no structural innovations. For reconsolidation paradigms specifically, metoprolol covers most of the same ground, and timolol is another option with similar CNS access. Propranolol has first-mover advantage in this niche and a denser associated literature, but its not uniquely irreplaceable in most bench designs.

What we like: the translational track record is definitive, and for performance anxiety studies, adrenergic probe work, or reconsolidation paradigms, its the right tool and the right reference. What we don’t like: the mechanism is fully characterized, the novelty is gone, and the questions propranolol can uniquely answer are getting fewer every year. A serious investigator building a new research program around propranolol in 2026 would need a very specific reason. This is a historical cornerstone, not a frontier compound.

Novelty

10

Mechanism promise

20

In-category differentiation

30

Evidence quality

80

Translational signal

80

Research bench value

50

Rationale Propranolol scores extremely low on novelty and mechanism — it’s a 1967 drug with single-receptor, fully-characterized pharmacology and no new chemistry — but pulls evidence and translational scores high owing to its approved-drug status across six indications and 60 years of clinical use; the PTSD memory reconsolidation angle is the most interesting current research use case, but Pitman’s foundational work is 24 years old and replication remains mixed, preventing a meaningful novelty rescue.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-selective beta-adrenergic antagonist

A non-selective beta-adrenergic antagonist; the first beta-blocker, repurposed for performance anxiety and migraine prophylaxis.

Abstract

Propranolol (1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 525-66-6; molecular formula C16H21NO2; molecular weight 259.34) is a non-selective beta-adrenergic antagonist developed by James Black at ICI and approved by the FDA in 1967 under the trade name Inderal. The compound is the first commercially successful beta-blocker, foundational to modern cardiovascular pharmacology. Beta-1 affinity is approximately equal to beta-2 affinity (non-selective). Plasma half-life is 3 to 6 hours; the lipophilic structure produces high CNS penetration, distinguishing propranolol from hydrophilic beta-blockers (atenolol, nadolol) for indications requiring central effect. Approved indications include hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor, and hypertrophic cardiomyopathy. Off-label use is extensive: performance anxiety (most common psychiatric indication), PTSD memory reconsolidation, akathisia, hyperthyroid tachycardia. The 5-HT receptor partial agonism (weak) was a former curiosity but is not clinically meaningful at standard doses. Used as the canonical non-selective beta-blocker reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-256Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pindolol

Plain-language summaryIntrigue 48 / 100

Pindolol is an old beta-blocker, FDA-approved in 1982, that lowers blood pressure by quieting the heart. What makes it interesting outside cardiology is a side activity: it binds tightly to a serotonin receptor (5-HT1A) that normally throttles serotonin release. By turning off that throttle alongside an SSRI antidepressant, pindolol was hypothesized to make the SSRI kick in faster (days rather than weeks). Trials produced mixed results, with some studies showing accelerated response in depression and others showing nothing. It is still used occasionally in psychiatry as an SSRI booster, but never became standard practice. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

37/100

Old beta-blocker with real 5-HT1A probe value, but inconsistent clinical signal limits excitement

Look, pindolol is one of those compounds where the mechanism is more interesting than the compound itself. Approved for hypertension in 1982, it spent years as a fairly unremarkable non-selective beta-blocker until researchers noticed something: it binds 5-HT1A receptors with real affinity (Ki around 50 nM) and acts as a partial agonist there. That property got it drafted into psychiatric research as an SSRI augmentor in the 1990s, and for a while it was genuinely intriguing.

The hypothesis was elegant. SSRIs lose their first two weeks to autoreceptor-mediated negative feedback at the raphe. Add a 5-HT1A partial agonist like pindolol, and you desensitize those presynaptic autoreceptors faster, in theory compressing the latency to antidepressant effect. Multiple placebo-controlled trials tested this through the late 1990s and into the 2000s. Some showed a real 1-2 week acceleration. Others did not. The meta-analyses are frustrating reading: positive signal on onset, weaker or null signal on overall efficacy. That inconsistency is the core problem with this compound as a research target, and we think it explains why the field mostly moved on.

Where pindolol still earns its place in a serious library is as a probe. Its specific combination of beta-blockade plus 5-HT1A partial agonism is hard to replicate with other tools. If you’re running mechanistic work on presynaptic serotonin autoreceptor desensitization, or trying to parse the cardiovascular from the serotonergic components of a drug interaction, pindolol gives you a handle thats difficult to replace. Its been called the canonical 5-HT1A binding beta-blocker in mechanism studies for good reason. Buspirone is more selective at 5-HT1A but lacks the beta component entirely. That combination makes pindolol genuinely useful for dissecting receptor contributions in mixed-pharmacology contexts.

What we dont love: the SSRI augmentation question is basically settled as disappointing, the compound is old enough that most interesting questions about it have been asked, and the short half-life (3-4 hours) is a practical nuisance in research designs. Its not a novel mechanism, not a novel compound, and the translational arrow from preclinical to clinical is pointing in different directions depending on which trial you read.

Honestly, if youre building a research program around serotonin autoreceptor biology and need a pharmacological tool with a specific dual profile, pindolol is worth having. As a primary research target in its own right? The case is thin. The probe utility is real but narrow, and the clinical inconsistency means the translational story never really closed.

Novelty

20

Mechanism promise

42

In-category differentiation

35

Evidence quality

45

Translational signal

35

Research bench value

52

Rationale Pindolol scores as a niche probe because its 5-HT1A autoreceptor work is genuinely useful for serotonin pharmacology, but the compound is a 1982 FDA approval with mixed augmentation trial data; bench utility saves it from obscurity, novelty and translational inconsistency drag the overall down.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-selective beta-adrenergic antagonist with 5-HT1A partial agonism

A non-selective beta-blocker with intrinsic 5-HT1A partial agonism; investigated as an SSRI augmenting agent.

Abstract

Pindolol (1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 13523-86-9; molecular formula C14H20N2O2; molecular weight 248.32) is a non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonism) and 5-HT1A partial agonism, approved by the FDA in 1982. The compound’s distinguishing pharmacological feature in psychiatric research is high-affinity 5-HT1A binding (Ki approximately 50 nM) with partial agonist activity at presynaptic autoreceptors; concurrent administration with an SSRI desensitizes the autoreceptor more rapidly than the SSRI alone, hypothetically accelerating the antidepressant response. Multiple placebo-controlled trials in the 1990s and 2000s reported faster onset (1 to 2 weeks shorter latency) but inconsistent overall efficacy improvement. Plasma half-life is 3 to 4 hours; metabolism is hepatic. Approved indications in cardiology include hypertension and angina; the SSRI augmentation use remains off-label. Used as the canonical 5-HT1A binding beta-blocker in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-257Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clonidine

Plain-language summaryIntrigue 60 / 100

Clonidine is a 1960s blood-pressure drug (sold as Catapres) that turned out to be unexpectedly versatile. It works by activating alpha-2 adrenergic receptors in the brainstem, dampening the sympathetic nervous system, the body’s stress response. That single mechanism explains why it lowers blood pressure, blunts opioid withdrawal symptoms, calms tics in Tourette syndrome, and reduces hyperactivity in ADHD (often as a non-stimulant alternative or add-on to stimulants in children). It is also used to manage hot flashes and as a sedating premedication. The drug is cheap, generic, and well-characterized, with sedation and rebound hypertension on abrupt discontinuation as the main downsides. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

45/100

Prototype alpha-2 agonist with real bench utility but essentially zero research novelty

Look, clonidine is not a research compound in any contemporary sense of the word. Boehringer Ingelheim synthesized it in the 1960s looking for a nasal decongestant, stumbled onto a central antihypertensive, and the FDA approved it in 1974. That backstory tells you a lot about where this thing sits in 2025: its mechanism was characterized before most of today’s investigators were born, and the pharmacology has not moved since.

The mechanism is presynaptic alpha-2A autoreceptor activation in the locus coeruleus, which dials down central noradrenergic tone. Secondary imidazoline I1 activity contributes to the blood pressure effect. Both of those stories are closed chapters in the literature. Theres nothing here that opens a new question; every pathway clonidine touches has been characterized to death, and the interesting molecular biology has moved to more selective tools. Dexmedetomidine is far more alpha-2A selective. Guanfacine has a cleaner CNS profile and is now the preferred agent for ADHD in most treatment algorithms. In differentiation terms, clonidine is the prototype that got superseded.

Where we do give clonidine some credit is bench utility. It remains the canonical alpha-2 reference standard for studies of noradrenergic regulation, locus coeruleus physiology, and sympathetic nervous system modulation. If you’re designing a study that needs a clean alpha-2 agonist as a positive control or pharmacological probe, clonidine is still what most labs reach for, partly because the literature comparator base is enormous. The PTSD-associated hyperarousal work, particularly the fear consolidation studies out of Pitman and Cahill’s groups, used clonidine as the reference intervention precisely because any new agent has to beat a known standard. That kind of indispensable-comparator role keeps the bench value score from cratering.

The translational and evidence scores are the only numbers that look strong here, and honestly they should, because this is an approved drug with decades of clinical use across four labeled indications. The rebound hypertension on abrupt discontinuation is one of the best-characterized discontinuation effects in all of pharmacology. But evidence quality for a research library score is about how much we’ve learned, not how much we’ve confirmed; at this point clonidine is all confirmation, no discovery.

We think this compound belongs in the library as a reference entry, not as something an investigator would build a program around in 2025. The score of 45 reflects that: real clinical and bench-utility credit, close-to-zero novelty and mechanism credit. Use it as the comparator arm, not the experimental arm.

Novelty

18

Mechanism promise

28

In-category differentiation

35

Evidence quality

78

Translational signal

72

Research bench value

65

Rationale Clonidine scores moderate overall on the strength of its well-validated clinical record and genuine utility as the reference alpha-2 agonist in noradrenergic research, but novelty and mechanism scores drag hard because this is a 1960s compound with a fully mapped single-receptor mechanism; more selective successors like dexmedetomidine and guanfacine have largely displaced it in both clinic and bench contexts.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Central alpha-2 adrenergic agonist

An imidazoline alpha-2 adrenergic receptor agonist; an antihypertensive repurposed for ADHD, opioid withdrawal, and Tourette syndrome.

Abstract

Clonidine (N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; CAS 4205-90-7; molecular formula C9H9Cl2N3; molecular weight 230.10) is an imidazoline alpha-2 adrenergic agonist developed at Boehringer Ingelheim in the 1960s and approved by the FDA in 1974 under the trade name Catapres. The compound activates presynaptic alpha-2A adrenergic autoreceptors in the locus coeruleus, reducing central noradrenergic outflow and producing centrally mediated reductions in sympathetic tone, blood pressure, and heart rate. Secondary imidazoline I1 receptor activity contributes to the antihypertensive effect. Plasma half-life is 12 to 16 hours; renal excretion is the principal clearance pathway. Approved indications include hypertension, ADHD (extended-release Kapvay), opioid withdrawal, and Tourette syndrome; off-label use in insomnia, hot flashes, and PTSD-associated hyperarousal. Rebound hypertension on abrupt discontinuation is a characteristic adverse effect. The compound is widely used in academic neuroscience as the prototype alpha-2 agonist for studies of noradrenergic regulation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-258Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pentoxifylline

Plain-language summaryIntrigue 42 / 100

Pentoxifylline (Trental) is a methylxanthine, structurally related to caffeine and theophylline, approved in 1984 for intermittent claudication (leg pain from peripheral artery disease while walking). Mechanism is weak, non-selective inhibition of phosphodiesterases (PDE3, 4, 5), but the practically meaningful effect is making red blood cells more deformable and reducing platelet aggregation, improving microcirculatory blood flow through narrowed vessels. Off-label exploration includes alcoholic hepatitis, vascular dementia, and tinnitus, with mixed results. The clinical effect in claudication is real but modest, and exercise therapy and surgical revascularization have largely overtaken it. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A 1984 approved hemorheologic workhorse with modest effects and limited modern research pull

Look, pentoxifylline is about as 1984 as it gets. Trental, Hoechst chemistry, methylxanthine scaffold. It inhibits PDE3, PDE4, and PDE5 with weak non-selective affinity, which raises intracellular cAMP and cGMP, and the net effect that made it commercially viable was improved erythrocyte deformability. Red blood cells that squeeze better through narrowed peripheral vasculature. That was enough to get an FDA approval for intermittent claudication and it sat there, quietly, for forty years.

The mechanism story is actually more layered than the initial approval suggested. Beyond hemorheology, pentoxifylline suppresses TNF-alpha production and has a modest anti-inflammatory footprint that generated off-label interest in cerebrovascular small-vessel disease, tinnitus, radiation fibrosis (the pentoxifylline plus tocopherol protocol has real data there), and more recently COVID-19 microvascular injury. There’s also a thread of hepatology literature exploring its anti-fibrotic properties via PDE4 inhibition. None of that is novel in 2026, but it does mean the compound isn’t purely a one-trick hemorheologic artifact. We give it credit for the multi-axis mechanism even if none of the axes are particularly fresh.

The differentiation problem is real. In the PDE inhibitor space, pentoxifylline is weak and non-selective, which makes it useful only where you specifically want weak and non-selective. PDE4 selectivity? Roflumilast is miles ahead. PDE5 selectivity? Sildenafil and tadalafil make pentoxifylline look like noise. As a hemorheologic reference compound it’s essentially the only approved agent in that category, which gives it a narrow differentiation moat, but that moat sits in a field most investigators aren’t actively farming.

Evidence quality is the strongest axis here, purely because it’s an approved drug with decades of trial data. Cochrane reviews of the intermittent claudication indication are real, and the effect size is modest but measurable. The radiation fibrosis protocol is one of the better-supported off-label applications we’ve seen in this class. But thats a ceiling, not a floor. The trial base is old, replication happened years ago, and what we’re left with is a well-characterized compound with no particularly exciting frontier.

Honestly, the main research utility in 2026 is as a reference probe. If you’re studying microvascular dynamics, erythrocyte mechanics, or weak pan-PDE biology and you need a pharmacologic anchor with an established safety profile and predictable behavior, pentoxifylline earns a place in the toolkit. It’s not the compound you build a program around. It’s the compound you use to establish a baseline while you test something more interesting alongside it.

Novelty

18

Mechanism promise

30

In-category differentiation

35

Evidence quality

62

Translational signal

52

Research bench value

42

Rationale Pentoxifylline scores low on novelty because it’s a four-decade-old FDA approval whose core mechanism (weak non-selective PDE inhibition plus erythrocyte deformability improvement) has been thoroughly characterized for decades; it retains modest bench utility as a reference hemorheologic probe but is clearly outclassed in the PDE inhibitor space by more selective agents and carries only modest translational signal even in its approved indication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylxanthine PDE inhibitor / hemorheologic agent

A methylxanthine non-selective phosphodiesterase inhibitor that improves erythrocyte deformability and microcirculation; used for intermittent claudication.

Abstract

Pentoxifylline (1-(5-oxohexyl)-3,7-dimethylxanthine; CAS 6493-05-6; molecular formula C13H18N4O3; molecular weight 278.31) is a methylxanthine non-selective phosphodiesterase inhibitor developed at Hoechst (now Sanofi) and approved by the FDA in 1984 under the trade name Trental. Mechanism: weak non-selective PDE inhibition (PDE3, PDE4, PDE5) increases intracellular cAMP and cGMP. The principal clinically meaningful effect is improvement in erythrocyte deformability and reduced platelet aggregation, producing improved microcirculatory blood flow. Approved for intermittent claudication. Off-label use in chronic cognitive impairment from small-vessel cerebrovascular disease, peripheral neuropathy, and tinnitus. Plasma half-life is approximately 0.4 to 0.8 hours; metabolism is hepatic. Used as a reference hemorheologic agent and weak non-selective PDE inhibitor.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-310Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 56 57 58 59 60 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.